Genetic Technologies EBITDA Margin 2010-2022 | GENE
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Genetic Technologies (GENE) over the last 10 years. The current EBITDA margin for Genetic Technologies as of December 31, 2022 is .
| Genetic Technologies EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.022B |
$0.005B |
|
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
|
